HAE: Haemonetics Corporation Company Profile & Statistics

About

Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. It acquired Pall Corporation's blood collection, filtration and processing product lines. It entered into a long-term supply agreement with Pall. The company acquired Hemerus Medical. It operates under 3 segments: Plasma, Blood Center, and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software. Hospital includes three product lines, namely, Hemostasis Management, Cell Salvage and Transfusion Management.

Info & Links

CEO

Christopher A. Simon

Headquarters

125 Summer Street
Boston, MA 02110, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

101

Employees

3,657

Haemonetics Corporation Statistics

Valuation Measures

Market Capitalization²

3.46B

Enterprise Value

4.37B

Enterprise Value/EBITDA(ttm)

13.89

Price to Earnings Ratio(ttm)

15.00

Price to Sales(ttm)

2.32

Price to Book(mrq)

3.51

Price to Cash(ytd)

10.48

Profitability

Gross Margin(ttm)

53.26%

Operating Margin(ttm)

15.72%

Profit Margin(ttm)

9.47%

Return on Equity(ttm)

23.66%

Return on Invested Capital(ttm)

6.34%

Return on Assets(ttm)

8.82%

Income Statement

Revenue(ttm)

1.37B

Revenue Per Share(ttm)

27.34

Gross Profit(ttm)

731.81M

EBITDA(ttm)³

314.28M

Net Income Available to Common(ttm)

130.06M

Diluted EPS(ttm)

2.54

Share Statistics

Beta (5Y Monthly)

0.39

52-Week Change

-10.19%

S&P 500 52-Week Change

12.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

50.24M

Dividend Yield

0.00%

Float⁴

49.33M

% Held by Insiders

1.80%

% Held by Institutions

99.67%

Balance Sheet

Total Cash(mrq)

320.85M

Total Cash Per Share(mrq)

6.39

Total Debt(mrq)

1.22B

Total Debt/Equity(mrq)

135.06%

Current Ratio(mrq)

3.97%

Quick Ratio(mrq)

2.55%

Book Value Per Share(mrq)

18.05

Cash Flow

Operating Cash Flow Per Share(ytd)

1.29

Free Cash Flow(ytd)

62.34M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

HAE

Haemonetics Corporation

Haemonetics Corporation Profile